ReviewPharmaceutics2022
PLGA-Based Nanomedicine: History of Advancement and Development in Clinical Applications of Multiple Diseases.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
126 citing papers in PubMed, 1 synthesis or guideline pooled it, 221 citations in OpenAlex.
- Combined PLGA scaffolds and therapeutic stem cells for locomotion recovery in spinal cord-injured rats: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- RNA therapeutics: current status and future directions.Signal transduction and targeted therapy · 2026Review
- Biofabrication and Characterization of Fluorapatite-Coated Poly(lactic-co-glycolic acid) Microscaffolds: Physicochemical Properties and Human Dental Pulp Stem Cell Responses.Journal of functional biomaterials · 2026Article
- Biomimetic Virus-Like Mesoporous Silica Nanoparticles Activate NK Cells Indirectly via Monocyte Crosstalk.Nano letters · 2026Article
- Engineering Hydrogels for Intrauterine Adhesion Therapy and Endometrial Regeneration.Gels (Basel, Switzerland) · 2026Review
- mRNA Therapeutics Beyond Infectious Diseases: Expanding Therapeutic Applications and Future Perspectives.Immunity, inflammation and disease · 2026Review
- Article
- Monodisperse PEG engineering for quantifiable surface conjugation on PLGA nanoparticles.Nanoscale advances · 2026Article
- Poly (lactic-co-glycolic acid) nanoplatforms for triple-negative breast cancer: current progress, advances, and future outlook.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Residual Content Impacts Critical Quality Attributes and Performance of Risperidone Microspheres.Pharmaceutical research · 2026Article
- PLGA - encapsulated harmine derivative H-2-168: A promising therapeutic agent for mitigating liver damage in hepatic hydatid disease.PLoS neglected tropical diseases · 2026Article
- Exploring the pivotal role of hot melt extrusion technology in developing PLGA based novel drug delivery platforms for better therapeutic outcomes.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- RSM optimization of Tetracycline-loaded PLGA nanoparticles in chitosan/HPMC hydrogels for sustained antibacterial delivery.Scientific reports · 2026Article
- Nanotechnology-based detoxification of profenofos using red blood cell membrane-coated polymeric nanoparticles.BMC pharmacology & toxicology · 2026Article
- Advancements in nanomaterial-based adjuvants for animal vaccines.Materials today. Bio · 2026Article
- Nanomedicine-based theranostics in atherosclerotic cardiovascular diseases.Journal of biomedical science · 2026Review
- PLGA Nanoparticle-based Anti-TLR2 scFv Gene Delivery for the Treatment of Alzheimer's Disease.Experimental neurobiology · 2026Article
- Iron-Based Nanoparticles as Delivery Tools.Pharmaceuticals (Basel, Switzerland) · 2026Review
- What If Trojan Horse Nanoparticles Could Change the Game for HPV Gene-Targeted Therapies?Journal of medical virology · 2026Review
- Nanostructured Lipid Carriers as Physicochemical Modulators of Complex Natural Extracts: Release Behavior and Bile-Induced Remodeling in Biorelevant Media.Molecules (Basel, Switzerland) · 2026Article
66 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research on the use of biodegradable polymers for drug delivery has been ongoing since they were first used as bioresorbable surgical devices in the 1980s. For tissue engineering and drug delivery, biodegradable polymer poly-lactic-co-glycolic acid (PLGA) has shown enormous promise among all biomaterials. PLGA are a family of FDA-approved biodegradable polymers that are physically strong and highly biocompatible and have been extensively studied as delivery vehicles of drugs, proteins, and macromolecules such as DNA and RNA. PLGA has a wide range of erosion times and mechanical properties that can be modified. Many innovative platforms have been widely studied and created for the development of methods for the controlled delivery of PLGA. In this paper, the various manufacturing processes and characteristics that impact their breakdown and drug release are explored in depth. Besides different PLGA-based nanoparticles, preclinical and clinical applications for different diseases and the PLGA platform types and their scale-up issues will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.